|Budget Amount *help
¥16,900,000 (Direct Cost: ¥13,000,000、Indirect Cost: ¥3,900,000)
Fiscal Year 2020: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
Fiscal Year 2019: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
Fiscal Year 2018: ¥5,720,000 (Direct Cost: ¥4,400,000、Indirect Cost: ¥1,320,000)
Fiscal Year 2017: ¥6,240,000 (Direct Cost: ¥4,800,000、Indirect Cost: ¥1,440,000)
|Outline of Final Research Achievements
In this study, we investigated the cell cycle control of iPS cell-derived cardiomyocytes. We identified that CCA-1 activated the cell cycle of iPS cell-derived cardiomyocytes and increased their proliferative capacity. In addition, we confirmed that the graft efficiency after cell transplantation was improved by transplanting cardiomyocytes treated with CCA-1 into infarcted hearts of immunodeficient mice. Further, comprehensive gene expression analysis identified genes that serve as markers for cell-cycle active cardiomyocytes.